Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 10:34 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 2,669 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control II Clear all
Completed Phase 2 Interventional Results available

A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients

NCT01951157
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
Docetaxel, Gemcitabine, Lurbinectedin (PM01183)
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Nov 1, 2026, 10:34 PM EST
Recruiting Phase 2 Interventional

Informing Oral Nicotine Pouch Regulations to Promote Public Health

NCT06315881
View directory record Official record
Conditions
Tobacco-Related Carcinoma
Interventions
Biospecimen Collection, Cigarette, Nicotine Oral Pouch, Smokeless Tobacco, Survey Administration, Text Message-Based Navigation Intervention
Procedure · Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
21 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Nov 1, 2026, 10:34 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Clinical Trial Assessing Toxicity and Efficacy of MF101 for Hot Flashes

NCT00119665
View directory record Official record
Conditions
Hot Flashes
Interventions
MF101
Drug
Lead sponsor
Bionovo
Industry
Eligibility
40 Years to 60 Years · Female only
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
4
States / cities
Birmingham, Alabama • San Francisco, California • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated May 17, 2007 · Synced Nov 1, 2026, 10:34 PM EST
Completed Phase 2 Interventional Results available

A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease

NCT01370811
View directory record Official record
Conditions
Sialorrhoea
Interventions
oxybutynin and clonidine oral solution treatment A, oxybutynin and clonidine oral solution treatment B, oxybutynin and clonidine oral solution treatment C, oxybutynin and clonidine oral solution treatment D
Drug
Lead sponsor
Orient Pharma Co., Ltd.
Industry
Eligibility
40 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Bingham Farms, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Nov 1, 2026, 10:34 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Nicotine and Tobacco Message Framing to Change Smoking Behavior in Diverse Groups of Young Adult Smokers

NCT06644664
View directory record Official record
Conditions
Tobacco-Related Carcinoma
Interventions
Health Education, Interview, Smoking Cessation Intervention, Survey Administration, Text Message-Based Navigation Intervention
Behavioral · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 35 Years
Enrollment
292 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Nov 1, 2026, 10:34 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Prevention of GBS Colonization Via Immunity

NCT00128219
View directory record Official record
Conditions
Beta Haemolytic Streptococcal Infection
Interventions
GBS III-TT, Tetanus and diptheria toxoids vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years · Female only
Enrollment
667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
3
States / cities
Augusta, Georgia • Pittsburgh, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Nov 1, 2026, 10:34 PM EST
Completed Not applicable Interventional

Effects of Potatoes on Blood Pressure in Persons With and Without Type 2 Diabetes Who Follow the DASH Diet for 6 Weeks

NCT05589467
View directory record Official record
Conditions
Type 2 Diabetes, Blood Pressure
Interventions
DASH-FP, DASH-NFP, Control
Other
Lead sponsor
Texas Tech University
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Nov 1, 2026, 10:34 PM EST
Completed Phase 2 Interventional

A Study of TL-925 as a Treatment for Dry Eye Disease

NCT05745064
View directory record Official record
Conditions
Dry Eye Disease
Interventions
TL-925, Placebo
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
4
States / cities
Newport Beach, California • Colorado Springs, Colorado • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Nov 1, 2026, 10:34 PM EST
Not listed Phase 3 Interventional

Transoral Gastroplasty for the Treatment of Morbid Obesity

NCT00661245
View directory record Official record
Conditions
Obesity
Interventions
TOGA, Control
Device
Lead sponsor
Satiety, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Worcester, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated May 5, 2009 · Synced Nov 1, 2026, 10:34 PM EST
Completed Not applicable Interventional Results available

Aligning Patient Preferences: a Role Offering Alzheimer's Patients, Caregivers, and Healthcare Providers Education and Support

NCT03323502
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
APPROACHES ACP Specialist Program, Standard of care
Behavioral · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
47,396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Warsaw, Indiana • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Nov 1, 2026, 10:34 PM EST
Completed Phase 1 Interventional

Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer

NCT01009437
View directory record Official record
Conditions
Breast Cancer
Interventions
ritonavir, therapeutic conventional surgery
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Minneapolis, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Nov 1, 2026, 10:34 PM EST
Completed Phase 2 Interventional Results available

Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2

NCT00085839
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Tarceva (Trademark) (erlotinib HCl, OSI-774), Combination carboplatin and paclitaxel
Drug
Lead sponsor
OSI Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
19
States / cities
Greenbrae, California • San Diego, California • Fort Lauderdale, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Nov 1, 2026, 10:34 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Health Literacy Assessment and Intervention to Reduce Disparities: FLIGHT/VIDAS II

NCT02922439
View directory record Official record
Conditions
Fatigue, Depression, Pain, Sleep Wake Disorders, Chronic Disease
Interventions
Tailored Intervention, Control Intervention
Behavioral
Lead sponsor
Nova Southeastern University
Other
Eligibility
40 Years and older
Enrollment
335 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Nov 1, 2026, 10:34 PM EST
Completed Early Phase 1 Interventional

NSAIDS Versus Opioids in Acute SER II Ankle Fractures

NCT02373254
View directory record Official record
Conditions
Ankle Fracture
Interventions
Ibuprofen, Acetaminophen/hydrocodone
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2017 · Synced Nov 1, 2026, 10:34 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Community Influences Transitions in Youth Health (CITY) Health II - Center for the Study of Community Health

NCT04320186
View directory record Official record
Conditions
Sexually Transmitted Diseases, HIV Infections
Interventions
Entertainment education, video
Behavioral · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 25 Years
Enrollment
334 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Nov 1, 2026, 10:34 PM EST
Terminated Phase 2 Interventional

Mifepristone as Adjunctive Therapy in Alzheimer's Disease

NCT00105105
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
Not listed
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
21
States / cities
Mesa, Arizona • Peoria, Arizona • Fountain Valley, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Nov 1, 2026, 10:34 PM EST
Completed Phase 2 Interventional Results available

A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

NCT04512066
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
RO6889450, Placebo, Risperidone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 45 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
24
States / cities
Little Rock, Arkansas • Bellflower, California • Culver City, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Nov 1, 2026, 10:34 PM EST
Completed Phase 2 Interventional Results available

Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

NCT01064622
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions
Gemcitabine Hydrochloride, Hydrocortisone/Placebo, Vismodegib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
21 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
25
States / cities
Beverly Hills, California • Duarte, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Nov 1, 2026, 10:34 PM EST
Completed Phase 2 Interventional Results available

Paxerol™ for Treatment of Nocturia - A Phase II Placebo-Controlled Trial

NCT02646826
View directory record Official record
Conditions
Nocturia
Interventions
Placebo, Paxerol - Dose Level 1, Paxerol - Dose Level 2, Paxerol - Dose Level 3
Other · Drug
Lead sponsor
Wellesley Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Brooklyn, New York • Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Nov 1, 2026, 10:34 PM EST
Completed Not applicable Interventional Results available

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

NCT00911508
View directory record Official record
Conditions
Atrial Fibrillation, Arrhythmia
Interventions
Left atrial ablation, Rate or Rhythm Control Therapy
Device · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
2,204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
76
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 66 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Nov 1, 2026, 10:34 PM EST
Completed Phase 2 Interventional

Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma

NCT04066725
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
Aspirin 81 mg, Aspirin 325mg, Placebo oral tablet
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 18, 2022 · Synced Nov 1, 2026, 10:34 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Surgical Theater's Surgery Rehearsal Platform

NCT02099318
View directory record Official record
Conditions
Cerebral Aneurysm Unruptured, Cerebral Aneurysm Ruptured
Interventions
Active SRP cases, Control cases
Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 5, 2017 · Synced Nov 1, 2026, 10:34 PM EST
Completed Phase 1Phase 2 Interventional Results available

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

NCT03193190
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Nab-Paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Fluorouracil, Atezolizumab, Cobimetinib, PEGPH20, BL-8040, Selicrelumab, Bevacizumab, RO6874281, AB928, Tiragolumab, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
12
States / cities
Duarte, California • San Francisco, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Nov 1, 2026, 10:34 PM EST
Completed Phase 2 Interventional

An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type

NCT00153010
View directory record Official record
Conditions
Alzheimer Disease
Interventions
NS 2330 (Tesofensine)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 85 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
80
States / cities
Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Nov 1, 2026, 10:34 PM EST